PRDM1, better known to many immunologists as BLIMP-1 or PRDI-BF1, was not discovered in lymphocytes at all. Its story began in the late 1980s, when researchers studying the human beta-interferon gene identified a protein that bound to positive regulatory domains of the interferon promoter and shut the gene down after viral induction. In 1991, AD Keller and Tom Maniatis characterized this novel repressor, and by 1994 the group of CA Turner and colleagues had recognized the same molecule, then named Blimp-1, as the factor capable of driving B lymphocytes to terminally differentiate into antibody-secreting plasma cells. That discovery cemented PRDM1’s reputation as a master regulator of lymphocyte differentiation, a role that has since been extended to T cells, innate lymphoid cells, and, crucially, natural killer cells.

Structurally, PRDM1 belongs to the PRDM family of transcriptional regulators, defined by a conserved PR domain at the amino terminus and a series of zinc finger motifs toward the carboxyl terminus. The zinc fingers provide sequence-specific DNA binding; remarkably, work from Keller and Maniatis showed that only two of the protein’s five zinc fingers are required for specific recognition of its target motifs. The PR domain, a relative of the SET domains found in histone methyltransferases, and the intervening regions mediate protein-protein interactions that allow PRDM1 to recruit an arsenal of chromatin-modifying machinery. This combination of direct DNA recognition and cofactor recruitment is what gives the protein its power as a transcriptional silencer.

Mechanistically, PRDM1 represses gene expression through several coordinated routes. It binds directly to promoters and regulatory regions of target genes, and it recruits co-repressors of the Groucho family, as demonstrated by B Ren and coworkers in 2000. In parallel, studies by Yu and colleagues showed that repression involves the recruitment of histone deacetylases, enzymes that strip acetyl groups from histone tails and compact chromatin into a transcriptionally silent state. PRDM1 also engages the histone H3 methyltransferase G9a, as reported by I Gyory and colleagues in Nature Immunology in 2004, adding repressive methylation marks to the chromatin landscape. Through this trio of mechanisms, direct binding, co-repressor recruitment, and epigenetic remodeling, PRDM1 can lock target genes into long-term silencing programs that define a cell’s identity.

In natural killer cells, PRDM1’s expression is itself tightly controlled by upstream transcription factors and cytokine signaling. The interleukin-21 pathway provides a well-characterized example: H Kwon and colleagues showed in 2009 that IL-21-induced regulation of the Prdm1 gene depends on functional cooperation between the STAT3 and IRF4 transcription factors. Other regulators of NK cell maturation, including T-bet, Zeb2, SMAD4, and the coactivator SRC-3, operate in overlapping networks that converge on the terminal differentiation program. PRDM1 sits at a critical junction in this hierarchy, translating environmental cytokine cues into stable changes in gene expression that push NK cells along their developmental trajectory.

The functional consequences of PRDM1 activity in NK cells are broad. Work by A Kallies and colleagues published in Blood in 2011 established a role for Blimp-1 in the transcriptional network controlling natural killer cell maturation, and subsequent studies have shown that PRDM1 influences effector cytokine production in human NK cells, as MA Smith and coworkers reported in the Journal of Immunology in 2010. PRDM1 also directly represses CD25, the IL-2 receptor alpha chain, thereby decreasing the sensitivity of human NK cells to IL-2-driven expansion, a finding from B Akman and colleagues in 2021 with clear implications for how NK cells are cultured and expanded for adoptive immunotherapy. Additionally, PRDM1 regulates transcription of CS1, also known as SLAMF7 or CD319, an immunotherapeutic target of major importance in multiple myeloma, linking this transcription factor directly to clinically exploited surface molecules.

Recent single-cell and functional studies have sharpened the picture further. Research presented by X Liu and colleagues at Blood meetings and published in Leukemia in 2026 demonstrated key regulatory roles for PRDM1 in human NK-cell differentiation and activation, including the promotion of primary human circulating CD56-dim NK-cell differentiation, the subset that carries out most cytotoxic killing in the blood. Related work by J He and colleagues in 2024 showed that Prdm1 positively regulates liver group 1 innate lymphoid cells, preserving their functional heterogeneity and supporting cancer immune surveillance in the liver. Beyond differentiation, PRDM1 participates in the universal transcriptional program of tissue residency shared with its partner Hobit, as LK Mackay and colleagues reported in Science in 2016, suggesting it helps NK cells establish themselves in tissues where they provide frontline defense.

The review’s authors are careful to draw an important distinction between what has been shown in vitro and what knockout phenotypes actually mean in vivo. The direct molecular functions of PRDM1, its DNA binding, co-repressor recruitment, and chromatin remodeling, have been characterized largely in isolated systems. In living animals, phenotypes observed in knockout mice reflect the integrated outcome of PRDM1 loss throughout NK cell development, differentiation, and homeostasis, in which compensatory mechanisms may operate. Consequently, such phenotypes cannot be attributed solely to the direct cell-intrinsic functions of the protein. This caveat matters for interpreting the literature and for designing experiments that aim to dissect PRDM1’s specific contributions at each stage of the NK cell lifespan.

PRDM1’s clinical significance extends well beyond normal NK cell biology, particularly in NK-cell malignancies. Extranodal NK/T-cell lymphoma, nasal type, an aggressive cancer frequent in East Asian and Latin American populations, frequently shows downregulation of PRDM1 through multiple mechanisms: genetic deletion of the 6q21 region where the gene resides, promoter hypermethylation, and aberrant expression of microRNAs such as miR-223 and miR-30a-5p. C Kucuk and colleagues established in 2011 that PRDM1 functions as a tumor suppressor gene in natural killer cell malignancies, and K Karube and coworkers identified PRDM1 and FOXO3 as tumor-suppressor candidates in NK-cell neoplasms through genomic and functional analyses. Paradoxically, in hepatocellular carcinoma, Q Li and colleagues reported in Nature Communications in 2022 that PRDM1 can induce cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis, a reminder that the same regulatory factor can play opposing roles depending on cellular context.

The synthesis offered by Zhao and Wang underscores why PRDM1 has become such a compelling target for translational immunology. A comprehensive map of the PRDM1 regulatory network provides profound insight into how NK cells achieve their mature, cytotoxic identity and how that identity can be corrupted in disease. For cancer immunotherapy, strategies that enhance PRDM1-dependent maturation could yield more potent NK cell products for adoptive transfer, while careful attention to contexts where PRDM1 promotes immune evasion will be essential. For autoimmune disorders, where dysregulated lymphocyte differentiation contributes to pathology, modulating PRDM1 activity offers a potential point of intervention. As the authors note, the historical arc from an interferon-gene repressor to a master regulator of innate immunity illustrates how deep mechanistic understanding of a single transcription factor can illuminate an entire field and point toward new medicines.

Subject of Research: The role of the transcription factor PRDM1 in natural killer cell maturation, gene regulation, and disease

Article Title: Role of PRDM1 in natural killer cells

Article References: Zhao, N., & Wang, Y. (2026). Role of PRDM1 in natural killer cells. Molecular Biology Reports, 53(1), Article 1720. https://doi.org/10.1007/s11033-026-12926-0

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12926-0

Keywords: PRDM1, BLIMP-1, natural killer cells, transcription factor, gene regulation, chromatin remodeling, NK cell differentiation, tumor suppressor, cancer immunotherapy, NK/T-cell lymphoma, epigenetics, innate immunity

The research team, led by scientists at Human Technopole in Milan, purified naive B cells, which have never encountered an antigen, and unswitched memory B cells, which carry the imprint of past infections, from the blood of healthy donors. They then activated both cell types in the laboratory using a cocktail that mimics T-cell-dependent stimulation: a cross-linker that engages the B cell receptor, multimeric CD40L to trigger the costimulatory CD40 receptor, and the cytokines IL-2 and IL-21. Over six days of culture, the researchers captured single-cell RNA sequencing and B cell receptor sequencing at four time points, from the resting state through the first cell division to full differentiation, retaining nearly 119,000 cells for analysis.

The first surprise came from comparing the two cell types at rest. At day zero, naive and memory B cells showed highly similar gene regulatory network activity, with a correlation of 0.89 across transcription factor regulons. Yet as activation progressed, the two populations drifted apart, and by day six the correlation had fallen to just 0.4. The transcriptional response to the very same stimulus was therefore profoundly cell-type-specific, with more than 3,000 genes differentially expressed between the two populations at the final time point.

That divergence translated into radically different fates. Memory B cells, when activated, almost exclusively differentiated into plasmablasts and plasma cells, the antibody factories of the immune system. Their gene expression was dominated by signatures of endoplasmic reticulum stress and the unfolded protein response, pathways such as IRE1α activating chaperones and XBP1(S) activating chaperone genes, which are hallmarks of cells ramping up massive antibody production. Naive B cells, by contrast, bifurcated. One branch produced plasma cells indistinguishable from those generated by memory cells, while the other adopted a germinal center phenotype marked by high expression of BCL6, CD81 and LIMK1, together with markers of memory precursors such as CCR6 and HHEX. An independent computational approach based on optimal transport, called Moscot, confirmed that germinal center cells arose almost exclusively from proliferating naive B cells, whereas plasmablasts could originate from either population.

The engine behind this fork in the road proved to be a pair of antagonistic transcription factors. The researchers applied the SCENIC framework to infer the activity of gene regulatory networks, or regulons, across the time course. They found that the activity of IRF4, the master driver of plasma cell differentiation, rose steadily in memory B cells from the earliest hours of activation and continued climbing throughout, culminating in expression of its downstream effector PRDM1. In naive B cells, IRF4 activity showed only a transient early increase before declining, persisting at high levels solely in the subset of cells that ultimately committed to the plasma cell fate. The activity of SPI1, also known as PU.1, behaved in exactly the opposite manner: strongly suppressed in memory cells, it rebounded in naive cells and peaked by day six, characterizing the germinal center state. Imaging flow cytometry revealed a mutually exclusive pattern of nuclear localization, with cells showing nuclear IRF4 consistently negative for nuclear PU.1 and vice versa, underscoring the antagonism between the two programs.

To test causality, the team deployed CRISPR-Cas9 to knock out IRF4 and PRDM1 in activated B cells, achieving knockout efficiencies of roughly 98 and 90 percent respectively. The consequences were dramatic. Loss of IRF4 blocked plasma cell differentiation in both naive and memory B cells and pushed the cells toward an aberrant germinal-center-like state that expressed canonical GC markers but differed transcriptionally from naturally arising germinal center cells by more than 2,600 genes. Knockout of PRDM1, in contrast, selectively eliminated plasma cells while preserving the capacity to form germinal center cells that were transcriptionally indistinguishable from those arising in control cultures. The conclusion is that PRDM1 is essential only for the plasma cell program, whereas IRF4 plays a dual and indispensable role, coordinating both plasma cell differentiation and proper germinal center development.

Perhaps the most conceptually striking finding concerns clonal behavior. By culturing only about 2,000 naive B cells and sequencing the entire culture at day six, the researchers identified 265 clones with at least ten cells each. A large proportion of these clones contained both plasma cells and germinal center cells, demonstrating that a single ancestral B cell can give rise to both fates. This rules out a simple population-level model in which different cells are pre-committed to different outcomes, and instead points to stochastic fluctuations in IRF4 expression within individual cells as the source of the bifurcation, particularly because the polyclonal stimulation system excludes any selection by antigen affinity.

The clonal analysis also revealed that gene expression itself is heritable. Sister cells within a clone showed significantly correlated expression of key plasma cell genes, including XBP1 and the immunoglobulin heavy chain gene IGHM, whereas random cell pairs from the same donor showed no such correlation. Genes regulated by XBP1 displayed especially strong intraclonal correlation, indicating that transcriptional programs central to the plasma cell lineage are inherited across cell divisions. To quantify this, the researchers trained three machine learning classifiers, logistic regression, a neural network and a random forest, to predict clonal identity from gene expression alone. Using a set of 369 genes with clonal correlation above 0.25, the logistic regression model correctly assigned sister cells with an average accuracy of nearly 88 percent, and the performance held up even after cell cycle and cell state effects were regressed out. Validation on eleven independent in vivo mouse B cell clonal datasets confirmed that the phenomenon is not an artifact of the culture system.

The study also shed light on antibody class switching, the process by which B cells replace the constant region of their antibody heavy chain to produce IgG, IgA or IgE while retaining antigen specificity. Using the sciCSR pipeline to quantify germline transcripts, the short non-coding RNAs that mark switch regions poised for recombination, the researchers found that more than 75 percent of germinal center cells expressed germline IGHG3, compared with only about 25 percent of plasma cells. Yet this priming did not translate into more switching, confirming that germline transcription is necessary but not sufficient for class switch recombination. Critically, by comparing IgM-positive cells from clones that contained switched cells with IgM-positive cells from entirely unswitched clones, the team found no transcriptional differences between the two groups. Belonging to a clonal lineage in which a sister cell has already switched therefore confers no increased predisposition to switch, providing direct experimental support for mathematical models proposing that class switching is a stochastic, cell-intrinsic event.

Together, these findings sketch a model in which each individual B cell is governed by a unique combination of competing gene programs that regulate cell state, clonal gene expression and isotype switching, maximizing the diversity of the immune response. Memory B cells carry an intrinsic bias toward plasma cell differentiation, driven by sustained IRF4 activity, yet they retain the latent capacity to adopt a germinal center fate when PRDM1 is suppressed, a discovery that could open new strategies for directing memory cells toward antibody refinement. Naive B cells, meanwhile, hedge their bets, with stochastic IRF4 dynamics splitting their progeny between immediate antibody secretion and the germinal center where future memory is made. As the authors note, gene regulatory network inference from single-cell transcriptomics remains inherently correlative, and future work with genome-wide transcription factor binding assays and high-throughput CRISPR screens will be needed to map the causal wiring in full. Even so, the study provides the most detailed picture yet of how human B cells decide their destinies, knowledge that is directly relevant to understanding responses to infection, vaccination and autoimmunity.

Subject of Research: Gene regulatory network dynamics controlling human naive and memory B cell differentiation and fate decisions

Article Title: Competing gene regulatory networks drive naive and memory B cell differentiation

Article References: Demela, P., Esposito, L., Marchesan, P., Nossa, L., Bolognini, D., Giacopuzzi, E., Ricciardelli, E., Ferrari, P., Bombelli, S., Peano, C., Prati, D., Valenti, L., & Soskic, B. (2026). Competing gene regulatory networks drive naive and memory B cell differentiation. Molecular Systems Biology, 22(7), 1097-1117. https://doi.org/10.1038/s44320-026-00207-8

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00207-8

Keywords: B cells, gene regulatory networks, plasma cells, germinal center, IRF4, PRDM1, single-cell RNA sequencing, CRISPR, class switch recombination, clonal tracking, immune memory, transcription factors